The bigger the better? … or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer

This publication has 16 references indexed in Scilit:

• A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study
  Annals of Oncology, 1997
• Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.
  Journal of Clinical Oncology, 1997
• Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
  Annals of Oncology, 1997
• Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
  Journal of Clinical Oncology, 1996
• 372 Neo-adjuvant chemotherapy in locally advanced beast cancer (LABC): FEC (5FU, epirubicin, cyclophosphamide) vs high dose intensity EC+G-CSF (Filgrastim). An EORTC—NCIC—SAKK study. Preliminary results of dose intensity (DI)
  European Journal Of Cancer, 1995
• High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
  Journal of Clinical Oncology, 1995
• c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
  New England Journal of Medicine, 1994
• Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
  New England Journal of Medicine, 1994
• The duke afm program intensive induction chemotherapy for metastatic breast cancer
  Cancer, 1990
• More is better.
  Journal of Clinical Oncology, 1988